These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39107853)

  • 1. Clinical trials with mechanism evaluation of intervention(s): mind the power and sample size calculation.
    Lee KM; Hellier J; Emsley R
    Trials; 2024 Aug; 25(1):527. PubMed ID: 39107853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Required sample size to detect mediation in 3-level implementation studies.
    Williams NJ; Preacher KJ; Allison PD; Mandell DS; Marcus SC
    Implement Sci; 2022 Oct; 17(1):66. PubMed ID: 36183090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriate statistical methods for analysing partially nested randomised controlled trials with continuous outcomes: a simulation study.
    Candlish J; Teare MD; Dimairo M; Flight L; Mandefield L; Walters SJ
    BMC Med Res Methodol; 2018 Oct; 18(1):105. PubMed ID: 30314463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Power and Sample Size Determination for Multilevel Mediation in Three-Level Cluster-Randomized Trials.
    Kelcey B; Xie Y; Spybrook J; Dong N
    Multivariate Behav Res; 2021; 56(3):496-513. PubMed ID: 32293929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental Power for Indirect Effects in Group-randomized Studies with Group-level Mediators.
    Kelcey B; Dong N; Spybrook J; Shen Z
    Multivariate Behav Res; 2017; 52(6):699-719. PubMed ID: 28967790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring mechanisms of action in clinical trials of complex surgical interventions using mediation analysis.
    Sharples L; Papachristofi O; Rex S; Landau S
    Clin Trials; 2020 Dec; 17(6):654-663. PubMed ID: 32815418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of Controlled Direct Effects in Longitudinal Mediation Analyses with Latent Variables in Randomized Studies.
    Loh WW; Moerkerke B; Loeys T; Poppe L; Crombez G; Vansteelandt S
    Multivariate Behav Res; 2020; 55(5):763-785. PubMed ID: 31726876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of causal mediation effects for a dichotomous outcome in multiple-mediator models using the mediation formula.
    Wang W; Nelson S; Albert JM
    Stat Med; 2013 Oct; 32(24):4211-28. PubMed ID: 23650048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size calculation for a stepped wedge trial.
    Baio G; Copas A; Ambler G; Hargreaves J; Beard E; Omar RZ
    Trials; 2015 Aug; 16():354. PubMed ID: 26282553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes.
    Vickerstaff V; Omar RZ; Ambler G
    BMC Med Res Methodol; 2019 Jun; 19(1):129. PubMed ID: 31226934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect effects in mediation analyses should not be tested for statistical significance.
    Twisk JWR
    J Clin Epidemiol; 2024 Jul; 171():111393. PubMed ID: 38750976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An imbalance in cluster sizes does not lead to notable loss of power in cross-sectional, stepped-wedge cluster randomised trials with a continuous outcome.
    Kristunas CA; Smith KL; Gray LJ
    Trials; 2017 Mar; 18(1):109. PubMed ID: 28270224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing Statistical Power in Mediation Models Without Increasing Sample Size.
    Fritz MS; Cox MG; MacKinnon DP
    Eval Health Prof; 2015 Sep; 38(3):343-66. PubMed ID: 24346658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intent-to-treat analysis of cluster randomized trials when clusters report unidentifiable outcome proportions.
    DeSantis SM; Li R; Zhang Y; Wang X; Vernon SW; Tilley BC; Koch G
    Clin Trials; 2020 Dec; 17(6):627-636. PubMed ID: 32838555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding Power Anomalies in Mediation Analysis.
    Wang K
    Psychometrika; 2018 Jun; 83(2):387-406. PubMed ID: 29181805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond total treatment effects in randomised controlled trials: Baseline measurement of intermediate outcomes needed to reduce confounding in mediation investigations.
    Landau S; Emsley R; Dunn G
    Clin Trials; 2018 Jun; 15(3):247-256. PubMed ID: 29552919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Controlled Trials 6: Determining the Sample Size and Power for Clinical Trials and Cohort Studies.
    Greene T
    Methods Mol Biol; 2021; 2249():281-305. PubMed ID: 33871850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.